前列腺癌的基础与临床研究：包括前列腺癌早期诊断的融合靶向精准穿刺活检；前列腺癌循环肿瘤细胞检测与临床意义; 前列腺癌微创手术的优化；前列腺癌手术中扩大淋巴结清扫的临床意义；寡转移前列腺癌的减瘤手术及其临床意义；PSMA-PET/CT在前列腺癌精准诊治中的应用，前列腺癌的基因检测与精准治疗；前列腺癌的耐药机制研究等。

前列腺癌的基础与临床研究：包括前列腺癌早期诊断的融合靶向精准穿刺活检；前列腺癌循环肿瘤细胞检测与临床意义; 前列腺癌微创手术的优化；前列腺癌手术中扩大淋巴结清扫的临床意义；寡转移前列腺癌的减瘤手术及其临床意义；PSMA-PET/CT在前列腺癌精准诊治中的应用，前列腺癌的基因检测与精准治疗；前列腺癌的耐药机制研究等。

作为主持人承担各级科研项目十余项，累计科研经费超200万，包括国家自然科学基金2项，入选上海市浦江人才计划等。以第一作者和通讯作者发表学术论文五十余篇，其中SCI论文三十余篇，多次国际会议口头发言，获中国发明专利授权两项，为多本SCI收录杂志审稿专家，参加多项全国多中心临床研究。作为主要参与者获教育部科学技术进步奖一等奖1项，华夏医学科技奖三等奖1项。

近五年的代表性论文：

1)     Guo H#, Jin C#, Ding L, Xie J, Xu J, Wang R, Wang H, GuoC, Zhang J, Peng B, Yao X, Yuan J*, Yang B*. De novo patientswith high-volume metastatic hormone-sensitive prostate cancer can benefit fromthe addition of docetaxel to triplet therapy: Network-analysis and systematicreview. Chin Med J (Engl). 2024 Sep 27. doi: 10.1097/CM9.0000000000003311.(PMID: 39350461, Article, Corresponding author, IF=7.5)

2)       Xie J#, Guo H#, Dong B#, Chen W#, Jin C, Xu Q, Ding L,Liu W, Dong S, Zhao T, Yu Y, Guo C, Yao X*, Peng B*, Yang B*.Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patientswith Metastatic Castration-resistant Prostate Cancer Progressing afterAbiraterone and Harboring DNA Damage Repair Deficiency: A MulticenterReal-world Study. Eur Urol Oncol 2024 Oct;7(5):1088-1096. (PMID: 38458891,Article, Corresponding author, IF=8.3).

3)       Liu W#, Kadier A#, Shen D, He Y, Dong S, Zhu K, Xu G,Zhao B, Mao S, Guo C, Yao X, Wei Q, Han D*, Yang B*. Combined MRI-TRUS fusiontargeted and systematic biopsy versus systematic biopsy alone for the detectionof prostate cancer: protocol for a prospective single-centre trial. BMJ Open,2024;14(3):e080593. (PMID: 38431292, Article, Corresponding author, IF=2.4).

4)       Yang B#*, Zhao T#, Dong B#, Chen W#, Yang G, Xie J, Guo C, Wang R, Wang H, HuangL, Peng B, Xue W*, Yao X*. Circulating tumor DNA and tissue complementarilydetect genomic alterations in metastatic hormone-sensitive prostate cancer.iScience, 2024;27(2):108931. (PMID: 38327772, Article, First author andCorresponding author, IF=4.6).

5)       Xu J, Ding L, Yang B*. Re: Michael S.Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with[(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistantProstate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase2 Trial. Lancet Oncol 2024;25:99-107. Eur Urol Oncol, 2024. (PMID: 38378399,Letter, Corresponding author, IF=8.3).

6)   Liu W, He Y, Yang B*.Re: Cathrine Alvaer Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, HenrikGronberg, Bjornar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in MostPatients with a Positive Stockholm3 Test and Negative Prostate MagneticResonance Imaging. Eur Urol Focus. In press.https://doi.org/10.1016/j.euf.2023.08.009. Eur Urol Focus, 2024. (PMID:38290858 , Letter, Co-Corresponding author, IF=4.8)

7)   Yang B#, Yang G#, Zhao F, Yao X, Xu L*, Zhou L*. AutologousEndothelial Progenitor Cells and Bioactive Factors Improve BladderRegeneration. Tissue Eng Part C Methods, 2024;30(1):15-26. (PMID: 37756374,Article, First author, IF=2.7).

8)   Ding L, Yang B*,Yao X*. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plusAbiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistantProstate Cancer (PROpel): Final Prespecified Overall Survival Results of aRandomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. EurUrol, 2023.(PMID: 38000965 , Letter,Co-Corresponding author, IF=25.3)

9)   Wang H#, Liu J#, Zhu X#, YangB*, He Z*, Yao X*. AZGP1P2/UBA1/RBM15 Cascade Mediates the FateDeterminations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect ofDocetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification.Research (Wash D C), 2023;6:0252.(PMID: 37854295, Article, Co-Correspondingauthor, IF=8.5)

10)  Wang R#, Xu Q#, Guo H#, YangG, Zhang J, Wang H, Xu T, Guo C, Yuan J, He Y, Zhang X, Fu H, Xu G, Zhao B, XieJ, Zhao T, Huang L, Zhang J, Peng B, Yao X*, Yang B*. Concordanceand Clinical Significance of Genomic Alterations in Progressive Tumor Tissueand Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer. CancerRes Commun, 2023;3(11):2221-2232. (PMID: 37877742, Article, Correspondingauthor， IF=2.0)

11)  Fu H, Liang S, Xu M, Guo J,Liu Q, Kang J, Zhang L, Liu Z, Ding L, Ma Y, Yang B, Yao X, Qi J,Wang H, Cai Y. An 18F-MD-PSMA (Multi-dentate PMSA Imaging Agent) PET/CT inProstate Cancer Relapse: Results of a Retrospective Trial. Curr Radiopharm,2023. doi:10.2174/1874471016666230915103157.( PMID: 37724670, Article, Co-author, IF=1.5)

12)  Song G, Li Y, Hou H, Wang Y,Wang X, Niu S, Tu X, Shen H, Zhou Z, Wang Y, Yan R, Xu N, Zhang G, Hao H, ZhangS, Liu B, Yang B, Wang B, Wang H, Huang H, Zhang Q, Dong B, Li Y,Bi J, Yan W, Guo H, Niu Y, Yang G, Liu M, Wei Q, Xing N. Indications,strategies, and development on prostate targeted biopsy: Report of thePanjiayuan Consensus Conference 2022. UroPrecision, 2023;1(1):3-19.

13)  Wang H#, Li N#, Liu Q#, Guo J,Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, ZhangG, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J*,Huang H*, Qin J*. Antiandrogen treatment induces stromal cell reprogramming topromote castration resistance in prostate cancer. Cancer Cell, 2023;41(7):1345-1362e1349. (PMID: 37352863, Article, IF=48.8)

14)  Xu G, Li JH, Xiang LH, YangB, Chen YC, Sun YK, Zhao BH, Wu J*, Sun LP, Xu HX. Transrectalultrasound examination of prostate cancer guided by fusion imaging ofmultiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targetedbiopsy. Asian J Androl, 2023;25(3):410-415. (PMID: 36348578, Article,Co-author, IF=3.0)

15)  Du X, Fei X, Wang J, Dong Y,Fan L, Yang B, Chen W, Gong Y, Xia B, Zhu H, Wu F, Wang Y, DongL, Zhu Y, Pan J, Yao X, Dong B. Early serial circulating tumor DNA sequencingpredicts the efficacy of chemohormonal therapy in patients with metastatichormone-sensitive prostate cancer. Translational Oncology, 2023;34:101701. (PMID: 37247504, Article, Co-author, IF=4.5)

16)  Xu T#, Guo H#, Xie J, He Y,Peng B, Che J, Yang B*,Yao X*. Sustained complete response tofirst-line immunochemotherapy for highly-aggressive TP53/MDM2-mutated uppertract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltratedcontexture and non-mesenchymal state: a case report and literature review.Front. Oncol. 2023.doi: 10.3389/fonc.2023.1119343. (PMID: 37427135, Co-Corresponding author, IF=3.5).

17)  Maskey N#, Mao S#,Yang G#, Guo Y, Kadier A, Yuan J, Xie J, Guo C, Yang B*,Yao X*. Perioperative change ofcirculating tumor cells in cytoreductive radical prostatectomy foroligometastatic hormone-sensitive prostate cancer: the preliminary safetyevidence from long-term oncologic outcomes. Int Urol Nephrol,2023;55(7):1709-1717. (PMID: 37160485, Article, Co-Corresponding author,IF=1.8).

18)  Xu T#, Gu W#,Wang X*, Xia L, He Y, Dong F, Yang B*, Yao X*. Distant metastasiswithout regional progression in non-muscle invasive bladder cancer: case reportand pooled analysis of literature. World J Surg Oncol, 2022;20(1):226. (PMID:35794571, Article, Co-Corresponding author, IF=2.5).

19)  Dong B#, YangB#, Chen W#, Du X#, Fan L#,Yao X*, Xue W*. Olaparib for Chinese metastatic castration-resistant prostatecancer: A real-world study of efficacy and gene predictive analysis. Medicaloncology, 2022;39(5):96. (PMID: 35599270, Article, Co-First author, IF=2.8)

20)  Yang G#, Xie J#,Guo Y, Yuan J,  Wang R,  Guo C, Peng B, Yao X*, Yang B*.Identifying the Candidates Who Will Benefit from Extended Pelvic Lymph NodeDissection at Radical Prostatectomy among Patients with Prostate Cancer. Front.Oncol. 2022. doi: 10.3389/fonc.2021.790183. (PMID: 35155191, Article,Co-Corresponding author, IF=3.5)

21)  Yang G#, Xie J#,Zhang S, Gu W, Yuan J, Wang R, Guo C, Ye L, Peng B, Yao X*, Yang B*.Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients WithOligometastatic Hormone-Sensitive Prostate Cancer Who Underwent CytoreductiveRadical Prostatectomy. Front. Oncol. 2022.11:812549. doi: 10.3389/fonc.2021.812549. (2022) (PMID: 35127528, Article,Co-Corresponding author, IF=3.5)

22)  Yang B*, Yang G, Yao X. Re: Karim A.Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus ExtendedPelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006. Eur UrolOncol. 2021. (PMID: 34535419, Letter, First author and Correspondingauthor, IF=8.3)

23)  Dong B#, Fan L#,Yang B#, Chen W#, Li Y#, Wu K#,Zhang F#, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L,Yao X*, Xue W*. Use of Circulating Tumor DNA for the Clinical Management ofMetastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-WorldStudy. J Natl Compr Canc Netw, 2021:1-10. (PMID: 33990090, Article,Co-First author, IF=14.8)